Triangle Securities Wealth Management Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Triangle Securities Wealth Management reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,783 shares of the medical research company’s stock after selling 89 shares during the period. Triangle Securities Wealth Management’s holdings in Amgen were worth $1,868,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Birch Capital Management LLC raised its holdings in Amgen by 3.4% in the 2nd quarter. Birch Capital Management LLC now owns 21,721 shares of the medical research company’s stock valued at $5,295,000 after buying an additional 708 shares during the period. Silvercrest Asset Management Group LLC raised its holdings in Amgen by 1.0% in the 2nd quarter. Silvercrest Asset Management Group LLC now owns 364,468 shares of the medical research company’s stock valued at $88,840,000 after buying an additional 3,546 shares during the period. Arlington Financial Advisors LLC raised its holdings in Amgen by 8.3% in the 2nd quarter. Arlington Financial Advisors LLC now owns 25,724 shares of the medical research company’s stock valued at $6,270,000 after buying an additional 1,962 shares during the period. Mather Group LLC. raised its holdings in Amgen by 25.4% in the 2nd quarter. Mather Group LLC. now owns 5,591 shares of the medical research company’s stock valued at $1,363,000 after buying an additional 1,134 shares during the period. Finally, Calamos Advisors LLC raised its holdings in Amgen by 29.4% in the 2nd quarter. Calamos Advisors LLC now owns 77,154 shares of the medical research company’s stock valued at $18,806,000 after buying an additional 17,549 shares during the period. Hedge funds and other institutional investors own 74.95% of the company’s stock.

Shares of Amgen stock opened at $203.97 on Thursday. Amgen Inc. has a one year low of $200.47 and a one year high of $276.69. The company has a market cap of $114.89 billion, a PE ratio of 21.01, a P/E/G ratio of 1.47 and a beta of 0.61. The company has a debt-to-equity ratio of 4.05, a quick ratio of 1.36 and a current ratio of 1.64. The business has a 50-day simple moving average of $209.99 and a 200-day simple moving average of $227.76.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $4.67 EPS for the quarter, topping the Zacks’ consensus estimate of $4.22 by $0.45. Amgen had a return on equity of 108.67% and a net margin of 21.77%. During the same quarter in the prior year, the firm earned $4.37 earnings per share. On average, sell-side analysts predict that Amgen Inc. will post 16.83 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 8th. Investors of record on Tuesday, November 16th will be issued a $1.76 dividend. This represents a $7.04 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Monday, November 15th. Amgen’s dividend payout ratio (DPR) is 72.50%.

Several analysts recently issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Amgen from $217.00 to $216.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 3rd. William Blair reaffirmed a “hold” rating on shares of Amgen in a research report on Friday, September 17th. Daiwa Capital Markets downgraded Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 target price for the company. in a research report on Thursday, September 23rd. Barclays dropped their target price on Amgen from $230.00 to $228.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 3rd. Finally, Morgan Stanley dropped their target price on Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 12th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $235.50.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Read More: Short Selling Stocks, A Beginner’s Guide

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.